Coya Therapeutics, Inc.
General ticker "COYA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $86.4M (TTM average)
Coya Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -2.9%.
Estimated limits based on current volatility of 2.0%: low 4.79$, high 4.99$
Factors to consider:
- Total employees count: 8 (0.0%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: No approved products, Clinical trial delays, Regulatory and compliance, Capital raising failure, Intellectual property risks
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.94$, 8.23$]
- 2026-12-31 to 2027-12-31 estimated range: [4.05$, 8.41$]
Financial Metrics affecting the COYA estimates:
- Positive: with PPE of -4.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Inventory ratio change, % of 6.17 > 4.02
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0
Short-term COYA quotes
Long-term COYA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $6.00MM | $3.55MM | $7.95MM |
| Operating Expenses | $13.91MM | $20.80MM | $30.50MM |
| Operating Income | $-7.90MM | $-17.25MM | $-22.56MM |
| Non-Operating Income | $0.64MM | $1.65MM | $1.33MM |
| R&D Expense | $6.04MM | $11.89MM | $19.02MM |
| Income(Loss) | $-7.26MM | $-15.60MM | $-21.22MM |
| Taxes | $0.72MM | $-0.72MM | $0.00MM |
| Net Income(Loss)* | $-7.99MM | $-14.88MM | $-21.23MM |
| Stockholders Equity | $35.64MM | $39.58MM | $43.03MM |
| Assets | $41.26MM | $44.35MM | $49.95MM |
| Operating Cash Flow | $-11.19MM | $-10.29MM | $-10.74MM |
| Investing Cash Flow | $-0.54MM | $-0.03MM | $-1.16MM |
| Financing Cash Flow | $38.43MM | $16.03MM | $20.39MM |
| Earnings Per Share** | $-0.79 | $-0.98 | $-1.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.